1. Home
  2. TECH vs AXSM Comparison

TECH vs AXSM Comparison

Compare TECH & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bio-Techne Corp

TECH

Bio-Techne Corp

HOLD

Current Price

$55.53

Market Cap

8.6B

Sector

Health Care

ML Signal

HOLD

Logo Axsome Therapeutics Inc.

AXSM

Axsome Therapeutics Inc.

HOLD

Current Price

$206.68

Market Cap

8.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TECH
AXSM
Founded
1976
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.6B
8.6B
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
TECH
AXSM
Price
$55.53
$206.68
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
17
Target Price
$71.82
$211.12
AVG Volume (30 Days)
1.8M
525.9K
Earning Date
05-06-2026
05-04-2026
Dividend Yield
0.62%
N/A
EPS Growth
N/A
38.56
EPS
0.49
N/A
Revenue
$1,219,635,000.00
N/A
Revenue This Year
$2.49
$57.24
Revenue Next Year
$6.40
$55.88
P/E Ratio
$106.04
N/A
Revenue Growth
5.23
N/A
52 Week Low
$46.05
$96.09
52 Week High
$72.16
$193.49

Technical Indicators

Market Signals
Indicator
TECH
AXSM
Relative Strength Index (RSI) 50.16 75.10
Support Level $49.55 $148.87
Resistance Level $58.04 N/A
Average True Range (ATR) 2.73 8.30
MACD -0.40 1.27
Stochastic Oscillator 38.90 74.89

Price Performance

Historical Comparison
TECH
AXSM

About TECH Bio-Techne Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

About AXSM Axsome Therapeutics Inc.

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Share on Social Networks: